📰 Priority Review News
Page 37 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
October 16, 2023
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 -- HUTCHMED Limited today announces that new and updated clinical data from several ongoing studies of fruquintinib, in...
October 16, 2023
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several
October 16, 2023
AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and 
October 16, 2023
AstraZeneca Plc's AZN supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority…
October 16, 2023
WILMINGTON, Del.--(BUSINESS WIRE)--Oct 16, 2023--
October 16, 2023
Osimertinib plus chemotherapy has been granted Priority Review for locally advanced or metastatic EGFR-mutated NSCLC.
October 12, 2023
Following the completion of all preclinical proof-of-concept, safety and specificity studies and toxicology studies required to commence a Phase 1 trial to...
October 12, 2023
/PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage biopharmaceutical company targeting the safer treatment of...
October 10, 2023
Orchard was founded in 2015 through a partnership between UCL Business (UCLB), the commercialisation company for UCL, and F-Prime Capital Partners. Its revolutionary treatments are the result of decades long gene therapy research and clinical work led by UCL Professors Bobby Gaspar and Adrian Thrasher, both based at UCL Great Ormond Street Institute of Child Health.
October 10, 2023
Cathie Wood’s investing philosophy is based on unwavering conviction in a portfolio heavily favoring high-growth names with disruptive qualities. But against an economic backdrop of soaring inflation and high interest rates, that strategy wilted during 2021 and 2022. However, Wood’s Ark Invest’s flagship ARKK fund appears to have got its mojo back this year, and looking ahead to the post-high rate landscape, that is something Wood expects will continue. “The fear of r...